| 1st ETA course, n = 1724 | 2nd ETA course, n = 338 | 3rd ETA course, n = 54 |
---|---|---|---|
All JIA | 1197 (69.4%) | 133 (39.4%) | 15 (27.6%) |
Systemic JIA | 91 (82.0%) | 12 (54.6%) | 3 (75.0%) |
Polyarticular arthritis, RF-negative | 370 (76.0%) | 40 (40.0%) | 7 (33.3%) |
Polyarticular arthritis RF-positive | 142 (80.7%) | 9 (36.0%) | 2 (50.0%) |
Persistent Oligoarthritis | 50 (68.5%) | 8 (57.1%) | 0 (0.0%) |
Extended Oligoarthritis | 204 (66.5%) | 25 (36.2%) | 1 (11.1%) |
Enthesitis-related arthritis | 190 (52.9%) | 25 (38.5%) | 1 (11.1%) |
Psoriatic arthritis | 109 (73.7%) | 10 (30.3%) | 1 (50.0%) |
Undifferentiated arthritis | 41 (65.1%) | 4 (40.0%) | 0 (0.0%) |
MTX at ETA stop/last observation | 631 (36.6%) | 79 (23.4%) | 8 (14.8%) |
Ever concomitant treatment with MTX | 1239 (71.9%) | 144 (42.6%) | 15 (27.8%) |
Duration of concomitant MTX therapy since start of ETA in patients who stopped MTX in years, mean (SD) | 1.5 (1.6) | 0.8 (1.5) | 0.2 (0.3) |